

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

(Present Status of Competition in the Pharmaceutical Industry)

WEDNESDAY, JULY 19, 1972

U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to notice, at 10:05 a.m., in room 4221, New Senate Office Building, Senator Gaylor Nelson (chairman of the subcommittee) presiding.

Present: Senator Nelson.

Also present: Benjamin Gordon, staff economist; and Elaine C. Dye, clerical assistant.

Senator NELSON. The hearing of the subcommittee will open.

This is a continuation of the hearings of the Small Business Committee's Subcommittee on Monopoly on Drug Procurement Policies of Federal Agencies.

This hearing was to have been held on June 20, but was postponed at that time because the OEO bill was on the floor of the Senate, and I was responsible for managing it. So, I apologize for any inconvenience caused by having to change the date.

Our first witness is Mr. Richard Seggel, Deputy Assistant Secretary for Health Policy Implementation.

Mr. Seggel, you are accompanied by your associates. Perhaps it would be helpful if you identified each of them for the purposes of the record, so the reporter will have their names, and if at any time any of them wishes to comment on any aspect, I would hope he would identify himself so that the reporter would have the right name.

Your statement will be printed in full in the record.

You may proceed to present it any way you desire. If you wish to elaborate on it at any time, or ask for any comments by any of your associates, feel free to do so.